The US Food and Drug Administration (FDA) has published final guidance on ‘Questions and Answers on Biosimilar Development and the BPCI Act’ and draft guidance on ‘New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3)’.
Both guidance documents aim to provide answers to common questions from prospective applicants and other interested parties regarding the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). The question and answer (Q&A) format is intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as describe FDA’s interpretation of certain statutory requirements added by the BPCI Act.
The final guidance entitled ‘Questions and Answers on Biosimilar Development and the BPCI Act’ was announced in a Federal Register post published on 20 September 2021. The guidance revises the final guidance document entitled ‘Questions and Answers on Biosimilar Development and the BPCI Act’ issued 12 December 2018.
Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry
Date: September 2021
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-biosimilar-development-and-bpci-act-guidance-industry
Following stakeholder feedback, FDA has withdrawn three Q&As, and has, as appropriate, incorporated suggested changes to the Q&A.
The draft guidance entitled ‘New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3)’ revises the draft guidance document entitled ‘New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2)’, issued 12 December 2018 to retain appropriate Q&As in draft.
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3)
Date: September 2021
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-and-revised-draft-qas-biosimilar-development-and-bpci-act-revision-3
The two documents cover a wide variety of topics associated with development of biosimilars including meetings with FDA, formulation, delivery devices, drug-drug interactions, dosage forms for injectable biosimilars, as well as the ‘nature and type of information’ needed related to post-approval manufacturing changes for a licensed biosimilar.
Electronic or written comments on the two guidance documents can be submitted to the Dockets Management Staff under Docket FDA-2011-D-0611. This can be done via the website www.regulations.gov or written comments can be mailed to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All written/paper submission should be clearly marked and identified as Docket FDA-2011-D-0611.
Related articles
FDA reaches 100 generic approvals
FDA issues final guidance on BCS-based biowaivers
| LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Regulación del registro de medicamentos biológicos en América Latina Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Regulación del registro de medicamentos biológicos en América Latina Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.
Source: Federal Register, US FDA
0
Post your comment